ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040)

FDA 510(k) K253801 · Anumana, Inc.

Substantially Equivalent

510(k) numberK253801

Submission

Device name
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040)
Applicant
Anumana, Inc.
Cambridge, MA, US
Received
November 28, 2025
Decision date
April 7, 2026
Decision
Substantially Equivalent (SESE)
Type
Traditional 510(k)
Summary
510(k) summary available from FDA

Official FDA 510(k) record

Device classification

Product code
SHP – Cardiac Amyloidosis Machine Learning-Based Notification Software
Device class
Class II (moderate risk)
Regulation
21 CFR 870.2380
Specialty
Cardiovascular

Cardiac Amyloidosis machine learning-based notification software employs machine learning techniques to suggest the likelihood of cardiac amyloidosis for further referral or diagnostic follow-up.

More from Anumana, Inc.

510(k)DeviceDecision
K260300WatchMate SoftwareQIH · Traditional 06/15/2026SE
K252360ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm (1020)SAT · Traditional 03/28/2026SE
K250652ECG-AI Low Ejection Fraction (LEF) 12-Lead algorithm (1010)QYE · Traditional 07/28/2025SE
K233160NeuTrace EP Mapping System v.2.1DQK · Traditional 11/25/2023SE
K232699Low Ejection Fraction AI-ECG AlgorithmQYE · Traditional 09/28/2023SE

Questions and answers

When was ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040) cleared by the FDA?

ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040) (K253801) received a 510(k) decision of Substantially Equivalent on April 7, 2026, 130 days after the submission was received.

What is the product code of K253801?

The FDA product code is SHP – Cardiac Amyloidosis Machine Learning-Based Notification Software, a Class II (moderate risk) device regulated under 21 CFR 870.2380.